MAKO Surgical Corp. Announces Appointment of Christopher R. Marrus as Senior Vice President of Sales

MAKO Surgical Corp. Announces Appointment of Christopher R. Marrus as Senior
Vice President of Sales

FORT LAUDERDALE, Fla., Feb. 21, 2013 (GLOBE NEWSWIRE) -- MAKO Surgical Corp.
(Nasdaq:MAKO), a medical device company that markets its RIO® Robotic Arm
Interactive Orthopedic surgical platform, MAKOplasty® joint specific
applications, and proprietary RESTORIS® implants that together enable
orthopedic surgeons to consistently, reproducibly and precisely treat patient
specific osteoarthritic disease, is pleased to announce the advancement of
Christopher R. Marrus to Senior Vice President of Sales.

"Chris has made valuable contributions as a sales leader since joining MAKO
over a year ago," said Maurice R. Ferré, President and CEO of MAKO. "Chris has
significant experience with both capital and procedural sales, which we
believe will greatly assist MAKO as we continue to sell additional RIO systems
while improving utilization across our installation base."

Mr. Marrus, 46, has been with MAKO since February 2012, most recently as
MAKO's Senior Director of Sales, East. Previously he served as MAKO's Regional
Sales Manager for RIO Sales, East, from February 2012 to January 2013.  Mr.
Marrus has worked in medical device sales for over fifteen years while
managing both capital and procedural sales, national accounts and clinical
training. From July 2010 to December 2011, he served as the Vice President of
U.S. Sales for EndoGastric Solutions, Inc., a medical device company that
develops surgical devices for reconstructive gastrointestinal procedures via a
transoral approach, where hewas responsible for domestic sales and clinical
training. From 2004 to 2010, Mr. Marrus held various positions with Intuitive
Surgical, Inc., a surgical robotic company, including Area Vice President,
where he managed a large portion of the company's national sales team and his
responsibilities included both capital and procedural sales. Mr. Marrus holds
a B.A. in History from Louisiana State University, and a J.D. from Tulane
University.

About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its RIO®
Robotic-Arm Interactive Orthopedic system, joint specific applications for the
knee and hip, and proprietary RESTORIS® implants for orthopedic procedures
called MAKOplasty®. The RIO is a surgeon-interactive tactile surgical platform
that incorporates a robotic arm and patient-specific visualization technology,
which enables precise, consistently reproducible bone resection for the
accurate insertion and alignment of MAKO's RESTORIS implants. The MAKOplasty
solution incorporates technologies enabled by an intellectual property
portfolio including more than 300 U.S. and foreign, owned and licensed,
patents and patent applications. Additional information can be found at
www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other
things, statements related to expectations, goals, plans, objectives and
future events. MAKO intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained in Section
21E of the Securities Exchange Act of 1934 and the Private Securities Reform
Act of 1995. In some cases, forward-looking statements can be identified by
the following words: "may," "will," "could," "would," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "continue," "ongoing," or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain
these words. These statements are based on the current estimates and
assumptions of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances, assumptions and
other factors that may cause actual results to differ materially from those
indicated by forward-looking statements, many of which are beyond MAKO's
ability to control or predict. Such factors, among others, may have a material
adverse effect on MAKO's business, financial condition and results of
operations and may include the potentially significant impact of a continued
economic downturn or delayed economic recovery on the ability of MAKO's
customers to secure adequate funding, including access to credit, for the
purchase of MAKO's products or cause MAKO's customers to delay a purchasing
decision, changes in general economic conditions and credit conditions,
changes in the availability of capital and financing sources for our company
and our customers, unanticipated changes in the timing of the sales cycle for
MAKO's products or the vetting process undertaken by prospective customers,
changes in competitive conditions and prices in MAKO's markets, changes in the
relationship between supply of and demand for our products, fluctuations in
costs and availability of raw materials and labor, changes in other
significant operating expenses, slowdowns, delays, or inefficiencies in MAKO's
product research and development cycles, unanticipated issues relating to
intended product launches, decreases in sales of MAKO's principal product
lines, decreases in utilization of MAKO's principal product lines or in
procedure volume, increases in expenditures related to increased or changing
governmental regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or foreign
regulatory requirements related to MAKO's current products, including
initiating and communicating product actions or product recalls and meeting
Medical Device Reporting requirements and other required reporting to the
United States Food and Drug Administration, or securing regulatory clearance
or approvals for new products or upgrades or changes to MAKO's current
products, developments adversely affecting our potential sales activities
outside the United States, increases in cost containment efforts by group
purchasing organizations, the impact of the United States healthcare reform
legislation enacted in March 2010 on hospital spending, reimbursement,
unanticipated changes in reimbursement to our customers for our products, and
the taxing of medical device companies, any unanticipated impact arising out
of the securities class action or any other litigation, inquiry, or
investigation brought against MAKO, loss of key management and other personnel
or inability to attract such management and other personnel, increases in
costs of retaining a direct sales force and building a distributor network,
unanticipated issues related to, or unanticipated changes in or difficulties
associated with, the recruitment of agents and distributors of our products,
and unanticipated intellectual property expenditures required to develop,
market, and defend MAKO's products. These and other risks are described in
greater detail under Item 1A, "Risk Factors," in MAKO's periodic filings with
the Securities and Exchange Commission, including MAKO's annual report on Form
10-K for the year ended December 31, 2011 filed on March 8, 2012. Given these
uncertainties, undue reliance should not be placed on these forward-looking
statements. MAKO does not undertake any obligation to release any revisions to
these forward-looking statements publicly to reflect events or circumstances
after the date of this press release or to reflect the occurrence of
unanticipated events.

"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo, whether
standing alone or in connection with the words "MAKO Surgical Corp." are
trademarks of MAKO Surgical Corp. 

CONTACT: Investors:
         MAKO Surgical Corp.
         954-628-1706
         investorrelations@makosurgical.com
        
         or
        
         Westwicke Partners
         Mark Klausner
         443-213-0500
         makosurgical@westwicke.com